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Abstract Assessment andmonitoring is important in diseases
affecting multiple sites and organs, such as axial
spondyloarthritis (axSpA) that may have several signs and
symptoms, and for which several treatments are available.
Instruments for assessment and monitoring should be appro-
priately validated, and it should be feasible to use them in
clinical practice as well as in clinical trials. The Assessment
in SpondyloArthritis International Society (ASAS) has devel-
oped core-sets of domains of disease and instruments to mea-
sure these domains, and recommends only the most important
domains being measured with the best available methods.
This article describes the ASAS core sets, as well as a few
recent developments in the field of assessment, to be applied
in clinical practice and research studies.
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Introduction
Spondyloarthritis, or better axial spondyloarthritis (axSpA) in
the context of this article, includes non-radiographic axSpA
(with clinical signs and symptoms of SpA, but without
characteristic radiographic changes on pelvic X-rays) and ra-
diographic axSpA (synonymous to ankylosing spondylitis
(AS)). AxSpA is a ‘system-disease’, with inflammation as
its main hallmark, that may affect many sites and structures
of the human body, and therefore may give a multitude of
various signs and symptoms. Each of these symptoms can
be assessed in clinical practice by a variety of instruments,
but it is obvious that this multitude does not contribute to a
better understanding of the disease, especially in the context of
patient care.
In order to create parsimony [1], the Assessment in
SpondyloArthritis International Society (ASAS) has
established a core set of variables to be formally measured
in patients with AS [2, 3]. Since symptoms and burden of
disease of nr-axSpA and AS do not importantly differ, ASAS
has proclaimed that this core set of variable is similarly appli-
cable to the entire spectrum of axSpA.
In this article, domains and instruments available for the
assessment and monitoring of nr-axSpA will be briefly
discussed in the context of the ASAS core set. In addition,
disease activity indices and response measures (reported in
clinical trials) will be mentioned.
The ASAS Core Sets
This ASAS/OMERACT core set of outcome measures spells
out the minimum of variables that should be collected for three
different settings: Bsymptom-modifying anti-rheumatic
drugs^ (SM-ARDs) and physical therapy, clinical record
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keeping and Bdisease-controlling anti-rheumatic treatment^
(DC-ART).
SM-ARDs are non-steroidal anti-inflammatory drugs
(NSAIDs). DC-ARTs in AS are tumor necrosis factor-alpha
(TNF-α) inhibitors and sulfasalazine.
The core set includes the relevant domains, but spe-
cific instruments have been selected for each domain
(Figs. 1 and 2).
Core Set of Symptom-Modifying Anti-rheumatic Drugs
and Physical Therapy
The inner circle of the ASAS/OMERACT core set describes
the domains that should be assessed in patients receiving SM-
ARDs and/or physical therapy. Specific instruments to assess
each of these domains are described below and can be found
on the website of the ASAS: www.ASAS-group.org
Physical Function
Physical function is an important outcome in axial SpA. Two
indices are used to measure function in axial SpA: the Bath
AS Functional Index (BASFI) and the Dougados Functional
Index (DFI) [4, 5]. BASFI includes 10 questions; 8 of them
refer to aspects of functional anatomy, and 2 pertain to the
ability to cope with everyday’s life. All questions are complet-
ed on numerical rating scales (NRS) or on a 10 cm visual
analog scale (VAS) with Beasy^ and Bimpossible^ as anchors.
The total BASFI-score is the average of the 10 questions and
ranges from 0 to 10.
Fig. 1 ASAS/OMERACT core
domains for ankylosing
spondylitis
Fig. 2 ASAS Core Set for DC-
ART* (1)
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The DFI is the second index that measures function in axial
SpA [6]. To date, the DFI is hardly ever used and no longer
recommended for clinical practice nor research.
Spinal Stiffness
BHow long does your morning stiffness last from the time you
wake up?^ This simple question is supposed to give insight
into the inflammatory symptom Bspinal stiffness^. The answer
is preferably recorded on an NRS or alternatively on a 10 cm
VAS with three anchors: B0 h,^ B1 h,^ and B2 or more hours^.
Scores range from 0 (none) to 10 (severe).
Patient Global Assessment
As in every rheumatologic condition, patient global assess-
ment is considered relevant in axSpA and assessed by the
question: BHow active was your spondyloarthritis last week?^
The answer is recorded on a NRS or on a VAS, and the score
ranges from 0 (not active) to 10 (very active).
Spinal Mobility Measurement
Many instruments have been developed to assess spinal mo-
bility. ASAS has positively recommended to assess chest ex-
pansion, modified Schober’s test, occiput-to-wall distance
(OWD), cervical rotation, and lateral spinal flexion [2, 3].
As an alternative for lateral spinal flexion, also the Bath AS
Metrology Index (BASMI) can be used [7]. The BASMI is an
index that combines five measures, slightly different as rec-
ommended above: tragus-to-wall distance (TWD), modified
Schober’s test, cervical rotation, lateral spinal flexion, and
intermalleolar distance. The measures will be briefly de-
scribed here, since there is often confusion about the optimal
methodology. Descriptions below are derived from the ASAS
handbook, to be checked on www.ASAS-group.org
(a) Chest expansion (only included in ASAS/OMERACT
core set)
The patient is asked to rest his hands on or behind the
head. The difference between maximal inspiration and
expiration is measured at the fourth intercostal level an-
teriorly in cm to the nearest 0.1 cm. Chest expansion is
measured twice, and the better of two tries is recorded.
(b) Modified Schober (included in ASAS/OMERACT core
set and BASMI)
The patient is standing erect. An imaginary line,
connecting both posterior superior iliac spines, is
marked. A second mark is placed 10 cm above the first
mark. The patient is asked to bend forward maximally,
and the distance between the twomarks is measured. The
increase in cm to the nearest 0.1 cm is recorded. The
modified Schober is measured twice, and the better of
two tries is recorded.
(c) Occiput to wall distance (included in ASAS/OMERACT
core set) and tragus to wall distance (included in BASMI)
The patient is standing with the heels and back resting
against the wall, with the hips and knees as straight as
possible. The chin should be held at the usual carrying
level. The patient is asked to put maximal effort to touch
the head against the wall. The distance between occiput
and wall is measured in cm to the nearest 0.1 cm. The
OWD is measured twice, and the better of two tries is
recorded.
(d) The TWD is measured with the patient in the same po-
sition as the OWD measurement. The distance between
the tragus and wall is measured twice in cm to the nearest
0.1 cm on the left side, and the better of two tries is
recorded. The same procedure is followed for the right
side. The final TWD is calculated by averaging the best
value for the left and the right side.
Both the OWD and TWD were found to be equally
reliable in assessing thoracic spine extension [8]. A lim-
itation of the TWD is that it can vary with the size of the
head. However, the TWD is less influenced by inclina-
tion of the cervical spine. The OWD is recommended by
ASAS, because (and in contrast with TWD) an OWD
value of 0 distinguishes a patient with a Bnormal^ tho-
racic spine extension from a patient with in kyphosis due
to axSpA [8].
(e) Cervical rotation (included in ASAS/OMERACT core
set and BASMI)
The patient is sitting straight on a chair, and the chin at
the normal carrying level. The assessor places a goniom-
eter at the top of the head in line with the nose. The
patient is asked to rotate the neck maximally to the left,
and the assessor follows with the goniometer. The angle
between the first sagittal plane and the new plane after
rotation is measured in degrees. The better of two tries is
recorded. The same procedure is followed for the right
side. The final score for cervical rotation is calculated by
averaging the best values for the left and the right side
and recorded in degrees.
(f) Lateral spinal flexion (included in ASAS/OMERACT
core set and BASMI)
The patient is standing with the heels and back resting
against the wall, without flexion in the knees and without
bending forward. A first mark is placed on the right thigh,
at the level of the patient’s middle fingertip. The patient is
then asked to bend sideward to the right as far as possible
without bending the knees or lifting the heels, and a sec-
ond mark is placed again at the level of the patient’s
middle fingertip. The distance between the two marks is
measured in cm to the nearest 0.1 cm. The better of two
tries is recorded. The same procedure is followed for the
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left side. The score for lateral spinal flexion is calculated
by averaging the best values for the left and the right side.
(g) Intermalleolar distance (only included in BASMI)
The patient is lying with the legs separated as far as
possible with the knees straight and the toes pointing
upwards. The distance between the medial malleoli is
measured in cm. Alternatively, the intermalleolar dis-
tance is measured with the patient standing erect and
the legs separated as far as possible. The better of two
tries is recorded.
(h) BASMI
The originally developed BASMI is called
BASMI-2. All 5 continuous measurements were
converted into a three-point scale (0 to 2) using a
conversion table [7]. The final BASMI-2 score is
calculated by summing the individual converted
scores and ranges from 0 to 10. Since converting a
continuous scale into a discrete scale with only 3
categories loses valuable information, a more exten-
sive scale with 11 categories called the BASMI-10
was investigated and outperformed the BASMI-2
[9].
A further extension of BASMI-10 was the
BASMI-linear, in which the continuous scores are
converted into a linear scale using five equations
[10]. The BASMI-linear score is calculated by the
mean of the five linear scores and ranges from 0 to
10. The BASMI-linear has shown to be more sensi-
tive to change in clinical trials compared with the
BASMI-2 and BASMI-10 [11]. Nowadays, ASAS
recommends to use either the BASMI-10 or the
BASMI-linear. Importantly, scores from the
BASMI-10 and BASMI-linear are not interchange-
able with the BASMI-2.
Pain
Pain is usually assessed in axial SpA by two standard ques-
tions: (a) BHow much pain of your spine due to AS do you
have?^ and (b) BHow much pain of your spine due to AS do
you have at night?^ The answers are recorded on a NRS or a
VAS with two anchors Bno pain^ and Bmost severe pain^ at
each side, respectively. Score ranges from 0 (no pain) to 10
(most severe pain).
Fatigue
“Howwould you describe the overall level of fatigue/tiredness
you have experienced?” is how fatigue according to ASAS
should be inquired in patients with axSpA. Scores (either on
NRS or on VAS) range from 0 (none) to 10 (very severe).
Core Set of Clinical Record Keeping
The core set of clinical record keeping includes the same do-
mains as the core set of SM-ARDs and/or physical therapy but
adds the domains: Bperipheral joints,^ Bentheses,^ and Bacute
phase reactants^.
Peripheral Joints
Peripheral joint involvement in axSpA is frequent and can be
assessed using the 44-joint count. Presence of swelling should
be recorded, and the total score varies from 0 to 44.
Entheses
Enthesitis is a typical characteristic of axSpA and means in-
flammation at these sites [12]. The first instrument for
assessing enthesitis in axSpA is known as the Mander
Enthesitis Index (MEI) [13]. Essentially, the MEI quantifies
the patient’s response to pain following local pressure to 66
entheseal sites and is scored on a Likert scale (0, no pain; 1,
mild tenderness; 2, moderate tenderness; or 3, tenderness se-
vere enough to elicit a wince or withdrawal). Alternatively,
more parsimonious indices have been proposed. These in-
clude the San Francisco Enthesitis Index (SFI) [14], the Berlin
Enthesitis Index (BEI) [15], and the Maastricht AS Enthesitis
Score (MASES) [16]. These instruments were found to reli-
ably reflect enthesitis in axSpA [17] and are included in the
ASAS/OMERACT core set for DC-ARTs. The SFI examines
17 sites with a scoring identical to the MEI [18]. The BEI
examines 12 sites [15]. Enthesitis is scored as 0 (absent) or 1
(present), which avoids an important part of inter-observer
variation. The MASES includes 13 sites and only takes values
per site of 0 (absent) or 1 (present) [16]. Other validated
enthesitis indices include the Spondyloarthritis Research Con-
sortium of Canada (SPARCC) Enthesitis Index (16 sites) and
the Leeds Enthesitis Index (LEI) (6 sites) [19, 20] but are not
(yet) included in the ASAS core sets. In general, ASAS does
not recommend the use of enthesitis indices in daily clinical
practice.
Acute Phase Reactants
Acute phase reactants are considered relevant in the core set of
clinical record keeping. An elevated erythrocyte sedimenta-
tion rate (ESR) or C-reactive protein (CRP) is only present
in 30–40 % of the patients, and it is good to realize that a
normal value does not preclude the presence of inflammation.
If there is peripheral joint involvement or inflammatory bowel
disease present in conjunction with axSpA, the acute phase
reactants are elevated more often [21]. Some suggest the use
of ESR or CRP for monitoring disease flares, or to predict a
more favorable response to treatment [22].
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Core Set of Disease-Controlling Anti-rheumatic
Treatments
The core set of DC-ARTs includes the same domains as the
core set of clinical record keeping and adds the domain “spine
radiograph”.
Radiographic Assessment of the Spine
A few scoring methods have been proposed for assessing
radiographic damage of the spine in axSpA. The best validat-
ed one, and the one recommended by ASAS, is the modified
Stoke AS Spine Score (mSASSS) [23]. In the mSASSS, the
anterior parts of the cervical and lumbar spine at a lateral view
are scored for the presence of squaring and/or erosion and/or
sclerosis (1 point per site), non-bridging syndesmophytes (2
points per site) and/or bridging syndesmophytes (3 points per
site or 6 points per vertebral unit). The total score ranges from
0 to 72.
Disease Activity Indices
Disease activity indices are increasingly popular and relevant
for monitoring disease activity in patients with axSpA, but not
yet included in the ASAS core set, since they are methodolog-
ically inferior [Bath AS Disease Activity Index (BASDAI)] or
simply too recent [AS Disease Activity Score (ASDAS)]. The
BASDAI [24] and the ASDAS [25] are the most important
indices available for clinical practice.
(a) BASDAI
The BASDAI includes six questions on fatigue (1),
spinal pain (2), peripheral joints (3), entheses (4), inten-
sity of morning stiffness (5), and duration of morning
stiffness(6) [24]. Each question is scored on an NRS or
on a 10 cm VAS, and the final BASDAI score is calcu-
lated by summing the first four questions and the average
of the last two questions, and divide the result by five.
The score ranges from 0 (no disease activity) to 10 (very
active disease). A cutoff of 4 is frequently used to define
active disease, but this cutoff level does not have a firm
justification. An important drawback of the BASDAI is
that it is entirely expert-driven. As a consequence, many
of the six items in the BASDAI are redundant (measuring
the same construct). Advantages of the BASDAI are that
it is easy to complete and very well known.
(b) ASDAS
The ASDAS is a data-driven index, partially based on
consensus, that combines questions (patient reported out-
comes (PROs)) about back pain (1), peripheral pain/
swelling (2), and duration of morning stiffness (3) (1–3
are derived from the BASDAI-questions), as well as the
“patient global assessment of disease activity” (4), with
either the ESR (ASDAS-ESR) or the CRP (ASDAS-
CRP)(5) in a weighted manner [25]. The ASDAS can
be calculated as follows:
ASDAS-CRP: 0:121  total back pain
þ 0:110  patient global þ 0:073
 peripheral pain=swellingþ 0:058
 duration of morning stiffness þ 0:579
 Ln CRPþ 1ð Þ:






 peripheral pain=swellingþ 0:069
 duration of morning stiffness þ 0:079
 total back pain:
The ASDAS-CRP is recommended by ASAS,
both for use in clinical practice and in clinical trials,
but the ASDAS-ESR may be used as well. Impor-
tantly, ASAS has formally validated cutoff levels for
disease activity states: an ASDAS value below 1.3 is
considered low disease activity, between 1.3 and 2.1
as moderate disease activity, between 2.1 and 3.5 as
high disease activity, and above 3.5 as very high
disease activity, with no maximum [26••].
Criteria for Response and Remission
Response criteria are intended to measure a response to treat-
ment. The ASAS-defined improvement criteria as well as
BASDAI and ASDAS can be used for defining improvement
or response in both clinical practice and in studies.
(a) ASAS 20 improvement criteria
The well-known “ASAS 20 improvement criteria” in-
clude four domains: patient global, pain, function
(assessed by BASFI), and inflammation (mean of
BASDAI questions 5 and 6) [27]. In order to meet an
ASAS 20 response, three of the four domains should
improve by at least 20 % and a minimum of one unit
on a scale of 0 to 10. In the remaining domain, there
should be no worsening of 20 % and a minimum of 1
unit, on a 0 to 10 scale.
(b) ASAS 40 improvement criteria
ASAS 40 improvement criteria include four domains,
identical to the ASAS 20 improvement criteria [28]. In
order to meet an ASAS 40 response, three of the four
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domains should improve by at least 40% and aminimum
of two units on a scale of 0 to 10. In the remaining
domain, there should be no worsening of 20 % and a
minimum of 1 unit, on a 0 to 10 scale.
(c) ASAS 5/6 improvement criteria
The ASAS 5/6 improvement criteria include six do-
mains: patient global, pain, function (assessed by
BASFI), inflammation (mean of BASDAI questions 5
and 6), CRP, and spinal mobility (assessed by lateral
spinal flexion) [28]. In order to meet an ASAS 5/6 im-
provement, there should be an improvement of at least
20 % in at least five of these six domains.
(d) ASAS partial remission
ASAS has defined a state of partial remission, which
reflects very low disease activity [28]. In order to fulfill
an ASAS partial remission state, a value of 2 (on a 0 to 10
scale) or less should be present in each of the following
domains: patient global, pain, function (BASFI), and in-
flammation (mean of BASDAI questions 5 and 6).
(e) BASDAI 50 response
ASAS has published a consensus statement for
the use of TNF-α inhibitors in patients with AS in
clinical practice [29]. Response to TNF-α inhibitors
is defined by improvement of at least 50 % in the
BASDAI score or an absolute change of 2 units (on
a 0 to 10 scale) after 3 months of treatment with
TNF-α inhibitors, together with an expert opinion
compatible with improvement.
(f) ASDAS improvement criteria
ASAS has also defined ASDAS-based response
criteria. According to the ASDAS improvement criteria,
a change in the score of at least 1.1 units is equivalent to a
“clinically important improvement,” and a change of at
least 2.0 units is called a “major improvement” [26••].
(g) ASDAS inactive disease
ASAS has defined cutoffs for disease activity states,
using the ASDAS score [26••]. A value below 1.3 is
considered Binactive disease^.
ASAS Health Index
Important complaints of patients with axSpA are, as said,
pain, fatigue, and limitation in activities and social par-
ticipation. Thus far, the instruments that have been
discussed here for the assessment of patients with SpA
focus predominantly on specific aspects of health such as
pain, disease activity, and physical function and measure
specific concepts like physical function. However, the
overall picture of impairments, limitations, and restric-
tions in activities or social participation of patients with
AS is not adequately assessed in SpA-specif ic
questionnaires. Most questionnaires are not conceptual-
ized with regard to their underlying construct. The Inter-
national classification of functioning, disability, and
health (ICF) Core Set for AS has served as an appropri-
ate template for developing a health index, since the
whole range of functioning and disability of patients with
axSpA is captured. Based on these assumptions, ASAS
has developed an instrument assessing health as opera-
tionalized by the ICF for patients with SpA. This ques-
tionnaire was developed using an item pool, linkage of
the items to the comprehensive ICF core set for AS and
testing of the item pool. The ASAS HI is a linear com-
posite index with 17 items, which cover most aspects of
the ICF core set [30••]. Preliminary validity has been
confirmed in a field test in four English-speaking coun-
tries. The ASAS HI will be used in clinical trials and in
clinical practice to test its real life performance and to
confirm that this new composite index captures relevant
information on functioning and health of patients with
axSpA.
Conclusions
Axial spondyloarthritis is a disease with multiple facets. It
is heterogeneous in its presentation, symptomatology, and
course. Rather than being associated with one unequivocal
outcome measure, axSpA has many Boutcome faces^. All
these outcomes can be measured, thus leaving the clinician
and researcher with residual uncertainty about the true val-
ue of these measures. ASAS has brought parsimony in this
multitude of outcome measures by prioritizing aspects of
validity and feasibility (core-sets), and has also developed
new instruments (e.g., ASDAS and ASAS-HI) that will
help to create better understanding of all aspects of axial
spondyloarthritis.
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